Drugs / Recombinant Human Thrombopoietin
Recombinant Human Thrombopoietin
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03673215 | Jun 2018 → Oct 2020 | cirrhosis of liver | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06630494 | Oct → Nov 2024 | — | 3SBIO AU PTY LTD | Completed | No outcome recorded |
| Phase 1 | NCT05193201 | Jan → Oct 2022 | liver disorder, thrombocytopenia | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT00003597 | Nov 1998 → Oct 2004 | cancer | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03014102 | Jun 2016 → Sep 2020 | — | Hongnan Mo | Unknown | No outcome recorded |
| Phase 1/2 | NCT00187109 | Jun 2000 → Feb 2007 | germ cell tumor, liver cancer, neuroblastoma, osteosarcoma +1 | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06673498 | Nov 2024 → Nov 2025 overdue | thrombocytopenia | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05634824 | Jan 2023 | autoimmune thrombocytopenia, pregnancy disorder | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05350956 | Jun 2022 → Jun 2023 | thrombocytopenia | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02094248 | Mar 2014 → Mar 2016 | infectious disease with sepsis, thrombocytopenia | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 2/3 | NCT01319669 | Feb 2011 → Aug 2016 | non-small cell lung carcinoma | Chinese Society of Lung Cancer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 34 trials | ||||||
| Phase 3 | NCT03492515 | May 2018 → May 2020 | autoimmune thrombocytopenia | Shandong University | Unknown | No outcome recorded |
| Phase 3 | NCT02139501 | May 2014 → Jan 2015 | autoimmune thrombocytopenia | Shandong University | Completed | No outcome recorded |
| Phase 3 | NCT01734044 | Jul 2012 → Jul 2014 | autoimmune thrombocytopenic purpura | Shandong University | Completed | No outcome recorded |
| Phase 3 | NCT01525836 | May 2011 → Dec 2013 | autoimmune thrombocytopenic purpura | Shandong University | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05217719 | Feb 2022 → Aug 2023 | pneumonia, thrombocytopenia | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02267993 | Oct 2014 → Aug 2018 | thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07476846 | Jun 2026 → Dec 2027 expected | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| — | NCT06955858 | May 2025 → Jul 2026 overdue | hemopoietic proliferation | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT07595133 Comparator | Jun 2026 → Dec 2027 expected | infectious disease with sepsis | Shanghai 10th People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07400341 Comparator | Jan 2026 → Jan 2028 expected | aplastic anemia, myelodysplastic syndrome | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 3 | NCT06440824 Comparator | Jun 2024 → Jun 2025 | thrombocytopenia | Shandong University | Unknown | No outcome recorded |
| Phase 3 | NCT05669079 Background | Aug 2023 → Aug 2026 overdue | — | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03515096 Comparator | Jul 2018 → Aug 2021 | disease related to hematopoietic stem cell transplant, thrombocytopenia | Shenzhen Second People's Hospital | Completed | Met primary |
| Phase 4 | NCT01379391 Comparator | Jun 2010 → Sep 2015 | disease related to hematopoietic stem cell transplant, thrombocytopenia | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human thrombopoietin | “Recombinant human thrombopoietin (rhTPO) is a glycoprotein molecule modified by full-length glycosylation and is of a similar pharmacological effect with endogenous...” NCT03515096 ↗24“rhTPO（Recombinant Human Thrombopoietin，TPIAO®” NCT02094248 ↗ |
| Known as | rhTPO | “Recombinant human thrombopoietin (rhTPO) is a glycoprotein molecule modified by full-length glycosylation and is of a similar pharmacological effect with endogenous...” NCT03515096 ↗11“This study aimed to evaluate the role of recombinant human thrombopoietin (rhTPO) before mobilization chemotherapy in facilitating leukapheresis in patients with lymphoma.” PMID 34505019 ↗ Jun 2021 “Recombinant human thrombopoietin (rhTPO), a full-length and glycosylated TPO with a molecular weight of 90 000 Daltons developed by 3SBIO (Shenyang, China)” NCT05634824 ↗ “rhTPO(recombinant human thrombopoietin) is given on the second, 4th and 9th day of the chemotherapy cycle in a dosage of 15000U once subcutaneously.” NCT01319669 ↗ “Preclinical studies and studies in adults have shown recombinant human thrombopoietin (rhTPO) to be effective in stimulating platelet production.” NCT00187109 ↗ “Recombinant human thrombopoietin for injection (rhTPO)” NCT06630494 ↗ “rhTPO（Recombinant Human Thrombopoietin，TPIAO®” NCT02094248 ↗ “Recombinant Human Thrombopoietin (rHTPO)” NCT01379391 ↗ “Recombinant Human Thrombopoietin（rhTPO）” NCT07476846 ↗ “Recombinant Human Thrombopoietin（rhTPO）” NCT06955858 ↗ “rhTPO(Recombinant human thrombopoietin)” NCT05350956 ↗ |
| Known as | rHuTPO | “Recombinant human thrombopoietin (rHuTPO) is a fully modified recombinant human thrombopoietin accurately expressed in mammalian cells.” NCT01379391 ↗ |
| Known as | Thrombopoietin | “Administer recombinant human thrombopoietin therapy. Thrombopoietin injection (specification: 15000 U/mL) is administered subcutaneously” NCT07595133 ↗ |
| Known as | TPIAO | “Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China” NCT01379391 ↗1“rhTPO（Recombinant Human Thrombopoietin，TPIAO®” NCT02094248 ↗ |
| Action | Activate | “TPO is a specific cytokine of megakaryocyte, which can promote the proliferation and maturation of macronuclear progenitor cells by binding to the receptor c-mpl.” NCT03515096 ↗ |
| Modality | Protein / enzyme biologic | “Biological: recombinant human thrombopoietin” NCT00003597 ↗ |
| Route | Intravenous | “recombinant human thrombopoietin IV on days 4, 6, 8, 10, and 12” NCT00003597 ↗ |